Grupo de Inversiones Suramericana SA 2021 Annual Report with Sustainability Disclosures
The report highlights Grupo SURA's performance in 2021, showcasing a strong recovery with consolidated net income reaching COP 1.5 trillion, approaching pre-pandemic levels. The company advanced its strategy of sustainable profitability through the integrated management of financial, social, human, and natural capitals. Key achievements include the creation of VaxThera to research and develop vaccines, and the successful management of major tender offers while maintaining robust corporate governance. Additionally, the company expanded its thematic ESG investments and progressed with its alignment to the TCFD framework.
Company: Grupo de Inversiones Suramericana SA
Sector: Finance & insurance
Country: Colombia
Year: 2021
Type: Annual Report with Sustainability Disclosures
Pages: 70
Back to company
Grupo de Inversiones Suramericana SA
Annual Report
The report highlights Grupo SURA's performance in 2021, showcasing a strong recovery with consolidated net income reaching COP 1.5 trillion, approaching pre-pandemic levels. The company advanced its strategy of sustainable profitability through the integrated management of financial, social, human, and natural capitals. Key achievements include the creation of VaxThera to research and develop vaccines, and the successful management of major tender offers while maintaining robust corporate governance. Additionally, the company expanded its thematic ESG investments and progressed with its alignment to the TCFD framework.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Employees